BRAF and serous adenocarcinoma: Several patients (n = 14) had a KRAS, NRAS, or BRAF activating mutation in the absence of a TP53 mutation, a genetic profile associated with low-grade serous carcinoma, mucinous carcinoma, and mesonephric-like adenocarcinoma46–48.